We are delighted to announce that Aitia will be at the Clinical Trials on Alzheimer’s Disease conference (CTAD) being held from October 24-27 in Boston, MA.

We will be presenting a poster focused on prediction of Amyloid PET positivity of Alzheimer’s Disease (AD) through Gemini Digital Twins of AD patients, based on blood-based biomarkers and clinical data discovered.

Details of the abstract and poster presentation are as follow:

Poster #82769

Abstract #00362

Theme: Clinical Trials: Biomarkers including plasma

Presentation Title: Prediction of Amyloid PET positivity from blood-based biomarkers and clinical data using AI-based Digital Twins

Information about CTAD 2023 can be found at https://www.ctad-alzheimer.com/